Imara to Present at Upcoming Investor Conferences

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) announced participation in three key virtual investor conferences in September 2021. The events include the Citi 16th Annual BioPharma Virtual Conference on September 10, where Dr. Rahul Ballal will discuss benign hematology, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring a pre-recorded presentation from Dr. Ballal. Additionally, on September 15, both Dr. Ballal and Dr. Ken Attie will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.

Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, and Ken Attie, M.D., Chief Medical Officer of Imara, will participate in a panel discussion titled “Sickle Cell, Beta-Thal, ITP & PKD Measuring Industry Progress in Benign Hematology” at the Citi 16th Annual BioPharma Virtual Conference on Friday, September 10, 2021 at 12:30 p.m. ET.

Dr. Ballal will give a pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference which will be made available on September 13, 2021 at 7:00 a.m. ET.

Dr. Ballal and Dr. Attie will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021 at 11:00 a.m. ET.

A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What are the upcoming conferences Imara Inc. will participate in?

Imara Inc. will participate in the Citi 16th Annual BioPharma Virtual Conference on September 10, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021.

When will Imara's presentation be available from the H.C. Wainwright conference?

Imara's pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be available on September 13, 2021, at 7:00 a.m. ET.

Who will represent Imara at the Citi BioPharma Conference?

Dr. Rahul Ballal, President and CEO, and Dr. Ken Attie, Chief Medical Officer, will represent Imara Inc. at the Citi 16th Annual BioPharma Virtual Conference.

How can I access Imara's presentations during the conferences?

Live webcasts of Imara's presentations will be available under 'Events and Presentations' in the Investors section of the company's website at www.imaratx.com.

What is the focus of Imara's business?

Imara Inc. focuses on developing novel therapeutics for patients with rare inherited genetic disorders of hemoglobin and other serious diseases, including treatments for sickle cell disease and beta-thalassemia.